The FDA has authorized use of the first prosthesis marketed in the U.S. for adults who have amputations above the...
Second Sight Medical announced positive three year results post-implant of its Argus II Retinal Prosthesis System from a multi-center clinical...
The FDA on 14 February 2013 approved the Argus II Retinal Prosthesis System from Second Sight Medical Products Inc., the...
A disease of more than 39.6 million people worldwide, HIV-1 infection has no curative therapy. To date, one man has achieved a sterile cure, with millions more hoping to avoid the potential pitfalls of lifelong antiretroviral therapy and other HIV-related disorders, including neurocognitive decline.
This guideline covers assessing and managing oesophago-gastric cancer in adults, including radical and palliative treatment and nutritional support.
The FDA on 9 May 2014 allowed marketing of the DEKA Arm System from DEKA Integrated Solutions being the first...
Sustained, drug-free control of HIV-1 replication is naturally achieved in less than 0.5% of infected individuals (here termed 'elite controllers'), despite the presence of a replication-competent viral reservoir.
This guideline covers the clinical care of adults (18 years and over) who are dying during the last 2 to 3 days of life.
This guideline is restricted to GI endoscopy but we cover elective and acute or emergency procedures.
This guideline covers rehabilitation strategies for adults who have experienced a critical illness and stayed in critical care.